Back to Search
Start Over
Strong antibody response after a first dose of a SARS-CoV-2 mRNA-based vaccine in kidney transplant recipients with a previous history of COVID-19
- Source :
- American Journal of Transplantation, American Journal of Transplantation, 2021, 21 (11), pp.3808-3810. ⟨10.1111/ajt.16764⟩
- Publication Year :
- 2021
-
Abstract
- A recent study demonstrated that a single dose of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA-based vaccine is sufficient to mount a robust immunological response in immunocompetent subjects with a previous history of coronavirus disease 2019 (COVID-19).1,2 While research has suggested that immunocompromised kidney transplant recipients (KTRs) who received mRNA-based vaccines show low immunization rates,3-5 the question as to whether this also applies to KTRs with a past history of COVID-19 remains unanswered. The aim of this study was to describe the results of immunization after one dose of the mRNA-1273 SARS-CoV-2 vaccine in KTRs who were already seropositive at baseline because of previous exposure to SARS-CoV-2.
- Subjects :
- 2019-20 coronavirus outbreak
COVID-19 Vaccines
Coronavirus disease 2019 (COVID-19)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Kidney transplant
Letter to the Editors
Immunology and Allergy
Medicine
Humans
Pharmacology (medical)
RNA, Messenger
Letter to the Editor
Transplantation
Messenger RNA
[SDV.MHEP] Life Sciences [q-bio]/Human health and pathology
business.industry
SARS-CoV-2
COVID-19
Kidney Transplantation
Transplant Recipients
Past history
Antibody response
Immunization
Immunology
Antibody Formation
business
[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Subjects
Details
- ISSN :
- 16006143
- Volume :
- 21
- Issue :
- 11
- Database :
- OpenAIRE
- Journal :
- American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
- Accession number :
- edsair.doi.dedup.....4f92dadcad8432096a9c5b5640a43237